Chief Investment Officer, Healthcare & Biotech
Chris Wood is Mauldin Economics’ chief investment officer for healthcare and biotech, as well as the chief investment officer at RiskHedge, a professional investment research firm focused on understanding and profiting from disruption.
A 16-year market veteran, he’s one of America’s most respected analysts and has the track record to prove it. His unique ability to consistently pinpoint stocks that double and triple has intrigued thousands of readers.
The Investment Strategy Where C.A.S.H. Is King
This premium alert service, with co-editors Chris Wood and Jake Weber at the helm, focuses on small-cap medical biotech companies with exceptional short-to mid-term profit potential. Their unique C.A.S.H. investing formula—Catalyst, Addressable Market, Science, Hype Potential—ensures that only the most promising candidates make it into the Biotech Millionaire portfolio.
In their premium alert service, they focus on small-cap, pre-revenue drug companies with exciting pipeline candidates in clinical trials. Their goal with each portfolio stock is to get at least a 100% return in the span of 12 to 24 months...
Monday's trading and (your recommendation’s) gain increased my portfolio in the amount of a year's wages after taxes!!!!! (...) Keep up the fantastic research!!"